GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in th
GSK has said that a regimen of PD-1 inhibitor Jemperli with PARP inhibitor Zejula has shown efficacy in the second stage of the RUBY trial, which could open up wider use i
A court in the UK has said that GSK should pay AstraZeneca a higher royalty rate on sales of ovarian cancer drug Zejula, which competes with AZ’s top-selling PARP inhibito
GSK has had another setback in its oncology business, after the FDA asked it to restrict use of its PARP inhibitor Zejula in ovarian, fallopian tube, or primary peritoneal cancer to patient